Erste Asset Management GmbH Invests $2.72 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Erste Asset Management GmbH purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 47,800 shares of the biopharmaceutical company's stock, valued at approximately $2,723,000.

Several other large investors also recently bought and sold shares of the stock. GAMMA Investing LLC boosted its position in shares of Halozyme Therapeutics by 96.6% in the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 254 shares during the period. International Assets Investment Management LLC purchased a new stake in Halozyme Therapeutics in the second quarter valued at approximately $33,000. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Halozyme Therapeutics in the second quarter valued at approximately $49,000. Toth Financial Advisory Corp purchased a new position in shares of Halozyme Therapeutics during the third quarter worth approximately $57,000. Finally, FSC Wealth Advisors LLC acquired a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at $65,000. Institutional investors and hedge funds own 97.79% of the company's stock.

Analysts Set New Price Targets

Several research analysts have issued reports on HALO shares. Wells Fargo & Company downgraded shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and raised their price objective for the stock from $58.00 to $62.00 in a research report on Monday, October 7th. HC Wainwright restated a "buy" rating and issued a $68.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, November 20th. Morgan Stanley increased their price objective on Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 7th. Cowen reiterated a "buy" rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Finally, JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and lifted their price objective for the company from $52.00 to $57.00 in a research report on Thursday, September 19th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $61.11.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO traded down $0.11 on Tuesday, reaching $48.48. 1,177,171 shares of the company were exchanged, compared to its average volume of 1,371,395. The company has a 50-day moving average of $52.93 and a 200-day moving average of $53.84. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The firm has a market cap of $6.17 billion, a price-to-earnings ratio of 16.05, a price-to-earnings-growth ratio of 0.44 and a beta of 1.23. Halozyme Therapeutics, Inc. has a 1-year low of $33.15 and a 1-year high of $65.53.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the business's stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $52.58, for a total transaction of $525,800.00. Following the sale, the chief executive officer now directly owns 676,744 shares in the company, valued at approximately $35,583,199.52. The trade was a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders have sold 60,000 shares of company stock worth $3,425,000. 2.70% of the stock is owned by company insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.